Risuteganib

• UNSPSC Description:

  Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina[1].

• Target Antigen:

  Integrin

• Type:

  Peptides

• Related Pathways:

  Cytoskeleton

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/risuteganib.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N(CCC1)[C@@H]1C(O)=O)[C@H]([C@H](O)C)NC([C@H](CS(=O)(O)=O)NC(CNC([C@@H](NC(CN)=O)CCCNC(N)=N)=O)=O)=O

• Molecular Weight:

  637.66

• References & Citations:

  [1]Nebbioso M, et al. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules. Int J Mol Sci. 2019 Apr 4;20(7). pii: E1693.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  1307293-62-4